Clinical trials: Relapsed Peripheral T-Cell Lymphomas
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00049504
- Testing
- cyclophosphamide, fludarabine phosphate, tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of…
- Conditions
- Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03598998
- Testing
- Pembrolizumab, Pralatrexate
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Lymphoma, T-Cell, Peripheral
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
This is a multicenter, single-arm, open label, study consisting of two cohorts. Cohort 2 explores the combination of copanlisib and pembrolizumab in patients with relapsed or refractory NKTCL, who have received at least 1 prior…
- Trial name
- NCT02535247
- Testing
- MK-3475, Copanlisib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have relapsed after achieving a complete response in…
- Trial name
- NCT01226472
- Testing
- KW-0761
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Peripheral T-cell Lymphoma
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin (GEMRO) regimen as salvage treatment in…
- Trial name
- FIL_GEMRO (NCT01822886)
- Testing
- Romidepsin + Gemcitabine
- Where
- 4 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00054327
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.
- Trial name
- NCT02314247
- Testing
- Selinexor
- Where
- 5 sites in Australia, Singapore
- Volunteers
- 16 people
- Sponsor
- Karyopharm Therapeutics Inc
Peripheral T-Cell Lymphoma
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.
- Trial name
- NCT02653976
- Testing
- SP-02L (darinaparsin for injection)
- Where
- 24 sites in Hong Kong, Japan and 2 more
- Volunteers
- 67 people
- Sponsor
- Solasia Pharma K.K.
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable
- Trial name
- NCT03075553
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Peripheral T-cell Lymphoma NOS, Mycosis Fungoides
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Background: Some T-cell lymphomas and leukemias do not respond to standard treatment. Researchers hope to develop a treatment that works better than current treatments.
- Conditions
- Peripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03905135
- Testing
- rhIL-15, Avelumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, T-Cell
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Historically cutaneous and peripheral T-cell lymphomas have response rates of approximately 30% to standard chemotherapy regimens.
- Trial name
- NCT02158975
- Testing
- MLN9708
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan Rogel Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT02676778
- Testing
- E7777
- Where
- 20 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Co., Ltd.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- GVHD (NCT00408681)
- Testing
- lithium carbonate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Leukemia, Lymphoma
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Giving chemotherapy drugs, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00619645
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
Lymphoma
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
RATIONALE: Combinations of biological substances in alefacept may be able to carry cancer-killing substances directly to cancer cells.
- Trial name
- NCT00438802
- Testing
- Alefacept
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body irradiation (TBI) and how well it works before donor stem cell transplant in…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00040846
- Testing
- alemtuzumab, fludarabine phosphate, total-body irradiation
- Where
- 7 sites in United States, Italy
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
This study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the previous treatment.
- Conditions
- T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepato-splenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma
- Trial name
- NCT02588651
- Testing
- Brentuximab vedotin
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Deepa Jagadeesh